Novartis (NYSE:NVS) (OTCPK:NVSEF) announced Thursday the acquisition of Kate Therapeutics, a San Diego-based gene therapy developer, for up to $1.1B. According to the deal terms, the Swiss ...

Cell and gene therapy is the hottest area in biotech at the moment, and Gilead’s $11.9bn acquisition of Kite Pharma in October has been followed by Celgene’s $9bn buyout of Juno Therapeutics.

The Novartis logo is seen on a new cell and gene therapy factory in Stein, Switzerland. (File photo by Arnd Wiegmann/Reuters) Swiss pharmaceutical giant Novartis announced it will spend $23 ...

Just a few weeks France's Sanofi made a $40 million investment in Gyroscope for first refusal rights on the gene therapy – called GT005 – but it is Novartis that has swooped on the company and ...

Extensive collaboration between various stakeholders in the field of cell and gene therapies ... global healthcare company Novartis. “Revolutions leading to new therapies, and evolutions to ...